Sultopride
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, IM |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 3–5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C17H26N2O4S |
| Molar mass | 354.46 g/mol |
| 3D model (JSmol) | |
| |
| |
| | |
|
WikiDoc Resources for Sultopride |
|
Articles |
|---|
|
Most recent articles on Sultopride |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Sultopride at Clinical Trials.gov Clinical Trials on Sultopride at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Sultopride
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Sultopride Discussion groups on Sultopride Patient Handouts on Sultopride Directions to Hospitals Treating Sultopride Risk calculators and risk factors for Sultopride
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Sultopride |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Sultopride (Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[1][2][3] It was launched by Sanofi-Aventis in 1976.[1] Sultopride acts as a selective D2 and D3 receptor antagonist.[4] It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[5]
References
- ↑ 1.0 1.1 José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
- ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
- ↑ European Drug Index, 4th Edition. Boca Raton: CRC Press. 1998. ISBN 3-7692-2114-1.
- ↑ Burstein, E. S.; Ma, J; Wong, S; Gao, Y; Pham, E; Knapp, AE; Nash, NR; Olsson, R; Davis, RE (2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–87. doi:10.1124/jpet.105.092155. PMID 16135699.
- ↑ Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". Eur J Pharmacol. 256 (2): 211–4. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Pyrrolidines
- Phenol ethers
- Sulfones
- Drug
